JP5734134B2 - 抗疲労用医薬組成物 - Google Patents
抗疲労用医薬組成物 Download PDFInfo
- Publication number
- JP5734134B2 JP5734134B2 JP2011186780A JP2011186780A JP5734134B2 JP 5734134 B2 JP5734134 B2 JP 5734134B2 JP 2011186780 A JP2011186780 A JP 2011186780A JP 2011186780 A JP2011186780 A JP 2011186780A JP 5734134 B2 JP5734134 B2 JP 5734134B2
- Authority
- JP
- Japan
- Prior art keywords
- fatigue
- present
- pharmaceutical composition
- composition
- action
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 11
- 230000002929 anti-fatigue Effects 0.000 title description 19
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 22
- ILKBHIBYKSHTKQ-UHFFFAOYSA-N Diisopropylamine dichloroacetate Chemical compound OC(=O)C(Cl)Cl.CC(C)NC(C)C ILKBHIBYKSHTKQ-UHFFFAOYSA-N 0.000 claims description 17
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 16
- 239000000174 gluconic acid Substances 0.000 claims description 16
- 235000012208 gluconic acid Nutrition 0.000 claims description 16
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 15
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 15
- 239000011581 pantethine Substances 0.000 claims description 15
- 229960000903 pantethine Drugs 0.000 claims description 15
- 235000008975 pantethine Nutrition 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 229940084113 diisopropylamine dichloroacetate Drugs 0.000 claims description 10
- 239000004227 calcium gluconate Substances 0.000 claims description 7
- 229960004494 calcium gluconate Drugs 0.000 claims description 7
- 235000013927 calcium gluconate Nutrition 0.000 claims description 7
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 7
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000176 sodium gluconate Substances 0.000 claims description 4
- 235000012207 sodium gluconate Nutrition 0.000 claims description 4
- 229940005574 sodium gluconate Drugs 0.000 claims description 4
- 229950006191 gluconic acid Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 description 20
- 230000009471 action Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Description
(1)パンテチンとジクロロ酢酸ジイソプロピルアミンを含有する医薬組成物;
(2)さらにグルコン酸またはその塩を含有する、(1)に記載の医薬組成物;
(3)グルコン酸の塩がグルコン酸カルシウムまたはグルコン酸ナトリウムである、(2)に記載の医薬組成物;
(4)疲労抑制剤である(1)〜(3)いずれか1項に記載の医薬組成物;ならびに、
(5)持久力向上用である(1)〜(3)いずれか1項に記載の医薬組成物;
である。
表1に記載の成分および分量をとり、日局製剤総則「錠剤」の項に準じて錠剤を製造する。
表2に記載の成分および分量をとり、日局製剤総則「液剤」の項に準じて錠剤を製造する。
(1)被検物質
0.5重量%カルボキシメチルセルロース溶液5mLに表3に記載の各化合物を溶解または懸濁し、試験液1〜4を投与当日に調製した。
Slc:SD雄性ラットの6週齢を日本エスエルシー(株)から購入し、設定温度23℃(許容範囲18〜28℃)、設定湿度55%(許容範囲30〜80%)、明暗各12時間(照明7〜19時)に制御されたラット飼育室内でラット用ブラケットテーパーケージに5匹ずつ入れ、飼料(CRF−1、オリエンタル酵母工業製)および水フィルターを通した水道水を自由に摂取させて約1週間予備飼育した。
コンピューターを用いて、無作為抽出法により各群の平均体重がほぼ均一になるように被験物質投与開始日に群分けを行った。午前中の1日1回5日間、各試験液を5mL/Kgとなるように経口投与した。なお、最終投与日は強制水泳約1時間以上前に投与し、試験液1を投与した群を対照群とした。
運動負荷試験は、ラットの体重を測定し、体重の8%の錘を尾根部にガムテープで取り付けた後、水道水の入った円形の水槽(直径18cm、高さ79cm、水深40cm、水温23±1℃)中に入れ、遊泳開始からラットの鼻部が水面から10秒間沈むまでの時間(水泳耐久時間)を計測する。
上記で得られた水泳耐久時間(秒)の結果を表4に示す。各値とも1群10匹の平均値である。
Claims (3)
- パンテチン、ジクロロ酢酸ジイソプロピルアミン及びグルコン酸またはその塩を含有する疲労抑制用医薬組成物。
- パンテチン、ジクロロ酢酸ジイソプロピルアミン及びグルコン酸またはその塩を含有する持久力向上用医薬組成物。
- グルコン酸の塩がグルコン酸カルシウムまたはグルコン酸ナトリウムである、請求項1もしくは2に記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011186780A JP5734134B2 (ja) | 2010-08-31 | 2011-08-30 | 抗疲労用医薬組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010194554 | 2010-08-31 | ||
JP2010194554 | 2010-08-31 | ||
JP2011186780A JP5734134B2 (ja) | 2010-08-31 | 2011-08-30 | 抗疲労用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012072127A JP2012072127A (ja) | 2012-04-12 |
JP5734134B2 true JP5734134B2 (ja) | 2015-06-10 |
Family
ID=46168724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011186780A Active JP5734134B2 (ja) | 2010-08-31 | 2011-08-30 | 抗疲労用医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5734134B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6697245B2 (ja) * | 2015-11-11 | 2020-05-20 | 株式会社ダイセル | 持久力向上剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006016357A (ja) * | 2004-07-02 | 2006-01-19 | Dai Ichi Seiyaku Co Ltd | 抗疲労組成物 |
JP2007006874A (ja) * | 2005-06-30 | 2007-01-18 | Takumi Sobo:Kk | 飲食物ベース組成物 |
JP5295571B2 (ja) * | 2005-12-28 | 2013-09-18 | ライオン株式会社 | 疲労回復用内服用液剤 |
JP2010138170A (ja) * | 2008-11-14 | 2010-06-24 | Daiichi Sankyo Healthcare Co Ltd | 抗疲労組成物 |
-
2011
- 2011-08-30 JP JP2011186780A patent/JP5734134B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2012072127A (ja) | 2012-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6942165B2 (ja) | ケルセチン配糖体を含有する筋萎縮抑制剤 | |
JP2010138170A (ja) | 抗疲労組成物 | |
TW200904406A (en) | Antifatigue agent | |
WO2010041647A1 (ja) | アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤 | |
CN105163731A (zh) | 内服组合物 | |
US20180104269A1 (en) | Composition for suppressing muscular fatty change | |
JP5734134B2 (ja) | 抗疲労用医薬組成物 | |
CN101801370A (zh) | 含有芝麻素类和花生四烯酸类的组合物 | |
JP2017052747A (ja) | ウロプラキン発現促進剤 | |
JP6100510B2 (ja) | 抗感冒剤 | |
EP3366288B1 (en) | Lithium ascorbate exhibiting anti-stress, anxiolytic and anti-depression activity | |
WO2021230146A1 (ja) | Nr及び/又はnmnとセサミン類とを含有する組成物 | |
JP7332489B2 (ja) | ホスホジエステラーゼ3阻害用組成物及び血小板凝集抑制用組成物 | |
JP7184805B2 (ja) | 肥満症の予防のためのベタイン | |
JP2012036167A (ja) | 内服液剤 | |
JP5775096B2 (ja) | インフルエンザの治療剤または予防剤 | |
JP4080350B2 (ja) | ビタミンuと硫黄含有酵母からなる抗関節炎食品 | |
US20130029996A1 (en) | Special composition for the use thereof as a drug | |
JP2016531141A (ja) | ジベンゾ−アルファ−ピロンを用いた体重増加制御 | |
JP2013028596A (ja) | 高温高湿度条件下において発症する疾病の予防又は改善剤 | |
JP2007137896A (ja) | イブプロフェン含有医薬製剤 | |
RU2007129408A (ru) | Способ выращивания поросят в период откорма | |
JP2009539941A (ja) | Slv308およびl−dopaを含んでなる組み合わせ製剤 | |
Ulemale et al. | Fluorosis in cattle. | |
JPWO2020158415A1 (ja) | オレキシン受容体拮抗阻害用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150319 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150406 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150414 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5734134 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |